Zura Bio (ZURA) Corporate presentation summary

Corporate overview and leadership

• Focused on advancing tibulizumab, a first-in-class bispecific antibody targeting IL-17 and BAFF pathways for complex immune disorders.

• Executive team and board include experienced leaders from major biopharma companies.

• Listed on Nasdaq under ticker ZURA, with $139M in cash as of September 30, 2025, funding operations through 2027.

Scientific and clinical strategy

• Tibulizumab fuses components from tabalumab (BAFF-binding) and ixekizumab (IL-17-binding), enabling dual-pathway inhibition.

• Designed to address efficacy ceilings of single-pathway therapies in autoimmune diseases by modulating both B-cell and T-cell driven pathobiology.

• Phase 1/1b data show potent target engagement, low immunogenicity, and a safety profile consistent with known pathway inhibitors.

Clinical development and pipeline

• Two ongoing Phase 2 trials: TibuSHIELD in hidradenitis suppurativa (HS) with topline data expected Q4 2026, and TibuSURE in systemic sclerosis (SSc) with data in 1H 2027.

• Both indications represent high unmet need and multi-billion-dollar market opportunities, with estimated TAMs of ~$8B (HS) and ~$4B (SSc) by mid-2030s.

• Platform offers optionality for expansion into additional autoimmune indications.